You’ve tried one antidepressant. Then another. Maybe a third, with a different mechanism, a different dosage, a different promise. And while some people do find meaningful relief through that trial-and-error process, a sobering number of people don’t. They go through the months of waiting to see if a drug “kicks in,” the side effects, the dose adjustments, and arrive somewhere roughly where they started – still depressed, still searching for something that works.
If that’s a familiar pattern, new research might be the most interesting thing you read this week. Because the drug at the center of it isn’t even a psychiatric medication. It’s an arthritis treatment.
The idea sounds counterintuitive at first. But there’s a growing body of evidence suggesting that for a significant portion of people with depression, the brain isn’t the primary problem. The immune system is. And researchers at the University of Bristol have just produced their most compelling evidence yet that targeting inflammation, rather than brain chemistry, might be the key to helping people who haven’t responded to anything else.
What Tocilizumab Is – and Why Researchers Tried It on Depression
Tocilizumab is a drug that’s been used for years to treat rheumatoid arthritis and other inflammatory conditions. It works by blocking a protein called interleukin-6, or IL-6, which is a signaling molecule that drives inflammation in the body. Think of IL-6 as one of the key alarm bells your immune system rings when it senses a threat. In autoimmune conditions like rheumatoid arthritis, that alarm goes off when it shouldn’t, causing the body to attack its own tissue. Tocilizumab quiets the alarm.
The new research, led by the University of Bristol and published in JAMA Psychiatry, investigated for the first time whether tocilizumab could improve symptoms of depression in people who hadn’t responded to standard antidepressant treatments.
Participants were randomly assigned to receive either tocilizumab (14 people) or a saltwater placebo (16 people) and were followed over four weeks to record any effects. Participants who received tocilizumab seemed to experience greater improvements over time across several measures compared to those given a placebo, including overall depression severity, fatigue, anxiety, and quality of life.
The sample size is small – only 30 participants total – and the researchers are careful to call it a pilot trial, meaning it’s designed to test whether a larger study is even worth doing. It is. The early numbers are striking.
The Numbers That Have Researchers Excited
Here is the statistic that cuts through the caution: the tocilizumab group was more likely to achieve full depression remission compared to the placebo group – 54% vs 31%. That works out to what researchers call a Number Needed to Treat of 5, meaning for every 5 patients treated with tocilizumab, one additional person achieves remission compared to placebo. For comparison, the NNT for SSRIs – the standard first-line antidepressants for moderate-to-severe depression – is about 7.
To put that in plain terms: based on this early data, tocilizumab appears to outperform the best antidepressants we currently have, at least for people whose depression is driven by inflammation. That’s a big “if,” and the researchers know it. But it’s an “if” that now has evidence behind it.
Current drug treatments for depression are solely based on targeting chemicals in the brain, such as serotonin, norepinephrine, and dopamine. Every SSRI prescription carries the assumption that depression is a brain chemistry problem. For some people, the evidence now suggests, that assumption is simply wrong.
The Inflammation Connection – A Third of People With Depression
Why would an immune-system drug help with depression at all? The answer lies in research that’s been building quietly for years. While depression is unlikely to be a purely “inflammatory” disease, evidence is accumulating that the two are closely connected. Approximately one-third of people with major depression show elevated inflammatory markers in their blood, even in the absence of any other medical illness.
Exposure to inflammatory signals leads to changes in neurotransmitter systems and brain circuits associated with depressive symptoms – and blocking those inflammatory signals can reduce depressive symptoms in people with depression. When the immune system is chronically overactivated, it can push the brain into a depressive state. No amount of serotonin adjustment fixes that.
Elevated inflammatory markers only occur in a subset of depressed individuals – and within that group, there appears to be a distinct population whose depression is primarily driven by inflammation. Researchers at Emory University have been pushing to have this officially recognized. Scientists there have provided compelling evidence supporting the existence of an inflammatory subtype of major depression, a development that could transform how the condition is diagnosed and treated.
The practical implication is significant: if you’re in that subset, standard antidepressants might always have been the wrong tool. Not because they’re ineffective in general, but because they’re targeting the wrong mechanism in your particular case.
What the Numbers Look Like in the US
Depression is not a small problem in America. The CDC reports that 2024 data show 1 in 20 US adults regularly report feelings of depression, and that 1 in 5 US adults have been told by a doctor that they have some form of depression disorder – a figure that was higher in 2024 than it was in 2023.
The subset who don’t respond to treatment is especially large. Only about one-third of people achieve meaningful remission with their first antidepressant, and another third go on to develop treatment-resistant depression, defined as the failure to respond to two antidepressants at adequate duration and dosage.
That means millions of Americans are cycling through medications, adjusting doses, trying combination therapies – all while remaining substantially depressed. By some estimates, treatment-resistant depression affects 30% or more of people diagnosed with major depressive disorder. If the inflammatory subtype accounts for roughly a quarter to a third of those cases, the population of Americans who might benefit from a tocilizumab-like approach runs into the millions. That’s not a fringe scenario – that’s a public health gap.
Could This Drug Actually Make It to the US?
This is where American readers face a genuinely complicated picture. The Bristol trial is a pilot. It’s promising, but it’s small – 30 participants followed for four weeks. Before tocilizumab could be prescribed for depression in the US, it would need to go through large-scale clinical trials, followed by an FDA review for a new indication.
The FDA has already approved multiple biosimilar versions of tocilizumab for inflammatory conditions in the US, including rheumatoid arthritis and giant cell arteritis. The first biosimilar received FDA approval in September 2023. The drug is not new to American regulators. It’s already being manufactured, prescribed, and administered across the country for other conditions. The infrastructure is there.
A biosimilar version called AVTOZMA (tocilizumab-anoh) was approved by the FDA in January 2025, covering the same indications as the original Actemra. The drug has already received FDA and European Commission approval, with multiple formulations available. Tocilizumab is, in other words, a known quantity as far as American regulators are concerned.
The question isn’t whether the drug can clear the FDA – it already has, for other conditions. The question is whether the mental health indication can be proven convincingly enough in larger trials to justify a new approval. That process typically takes years.
There are some signals that it will move forward. A triple-blind randomized trial of tocilizumab for treatment-resistant depression is already registered on ClinicalTrials.gov, with recruitment expected to begin in mid-2025, suggesting international momentum behind this approach. If that trial and others produce results consistent with the Bristol pilot, the case for FDA review becomes considerably stronger.
The other factor worth watching is the growing scientific push to officially classify inflammatory depression as a distinct subtype – separate from “standard” major depressive disorder. If that classification takes hold in the DSM (the manual American psychiatrists use to diagnose mental health conditions), it would create a clearly defined patient population for which an anti-inflammatory treatment could be FDA-reviewed and approved. Some researchers are already calling for exactly that.
Read More: Habits Displayed By Mentally Strong People Who Won’t Let Life Break Them
What to Do With All of This
None of this will change anyone’s prescription in the next year or two in the US. The path from a 30-person pilot trial in the UK to an FDA-approved indication is long, expensive, and uncertain. Anyone who tells you otherwise is getting ahead of the evidence.
But here is what the research does shift: for decades, treatment-resistant depression has largely been treated as a mystery – a case of the brain being particularly stubborn, requiring ever-escalating combinations of drugs that all work on the same basic principle. What researchers are now describing is something more specific: a biological mechanism that current treatments don’t address at all, affecting a real and identifiable group of people.
If you’ve tried two or three antidepressants and gotten nowhere, that’s not evidence that your depression is untreatable. It may mean you were given the right treatment for the wrong type. Depression has never been one thing, and the science is finally starting to reflect that. Knowing it doesn’t give you a new prescription yet – but it does give you a better question to take into your next doctor’s appointment.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.